RU2556205C2 - Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения - Google Patents

Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения Download PDF

Info

Publication number
RU2556205C2
RU2556205C2 RU2012131344/04A RU2012131344A RU2556205C2 RU 2556205 C2 RU2556205 C2 RU 2556205C2 RU 2012131344/04 A RU2012131344/04 A RU 2012131344/04A RU 2012131344 A RU2012131344 A RU 2012131344A RU 2556205 C2 RU2556205 C2 RU 2556205C2
Authority
RU
Russia
Prior art keywords
pyrrolo
dihydro
dione
trans
indol
Prior art date
Application number
RU2012131344/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2012131344A (ru
Inventor
Дэвид П. РИД
Нил Р. БАРНС
Джон К. КЕЙН
Кристофер А. ЛИ
Цзянь-Се ЧЭНЬ
Мартин П. РЕДМОНД
Original Assignee
Аркьюл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аркьюл, Инк. filed Critical Аркьюл, Инк.
Publication of RU2012131344A publication Critical patent/RU2012131344A/ru
Application granted granted Critical
Publication of RU2556205C2 publication Critical patent/RU2556205C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2012131344/04A 2009-12-23 2010-12-21 Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения RU2556205C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289,563 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (2)

Publication Number Publication Date
RU2012131344A RU2012131344A (ru) 2014-01-27
RU2556205C2 true RU2556205C2 (ru) 2015-07-10

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012131344/04A RU2556205C2 (ru) 2009-12-23 2010-12-21 Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения

Country Status (19)

Country Link
US (3) US8552192B2 (enExample)
EP (2) EP2515904A4 (enExample)
JP (2) JP2013515737A (enExample)
KR (2) KR101669707B1 (enExample)
CN (2) CN104910159A (enExample)
AU (2) AU2010336533B9 (enExample)
BR (1) BR112012015656A2 (enExample)
CA (1) CA2785503A1 (enExample)
CO (1) CO6561823A2 (enExample)
HK (1) HK1215025A1 (enExample)
MX (1) MX2012007259A (enExample)
MY (2) MY169232A (enExample)
NZ (2) NZ600800A (enExample)
PH (2) PH12012501293A1 (enExample)
RU (1) RU2556205C2 (enExample)
SG (1) SG181927A1 (enExample)
TW (3) TWI557125B (enExample)
WO (1) WO2011079142A2 (enExample)
ZA (1) ZA201204759B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
KR20140146036A (ko) * 2011-07-07 2014-12-24 아르퀼 인코포레이티드 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR20250070131A (ko) * 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A4 (en) * 2021-04-07 2025-03-19 Crystalys Therapeutics, Inc. URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083580C1 (ru) * 1991-08-23 1997-07-10 Кали-Хеми Фарма ГмбХ 1,7-анеллированные производные 3-(пиперазиноалкил)-индола, способ их получения (варианты), содержащая их фармацевтическая композиция и промежуточный продукт для их получения

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE315017T1 (de) * 2002-07-31 2006-02-15 Firmenich & Cie Verfahren zur racematspaltung einer sclareolid- vorstufe
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2690782C (en) * 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083580C1 (ru) * 1991-08-23 1997-07-10 Кали-Хеми Фарма ГмбХ 1,7-анеллированные производные 3-(пиперазиноалкил)-индола, способ их получения (варианты), содержащая их фармацевтическая композиция и промежуточный продукт для их получения

Also Published As

Publication number Publication date
PH12012501293A1 (en) 2013-01-07
AU2015243015B2 (en) 2017-02-02
KR20160121602A (ko) 2016-10-19
AU2010336533B9 (en) 2015-10-08
CN104910159A (zh) 2015-09-16
KR101669707B1 (ko) 2016-10-27
NZ628087A (en) 2016-02-26
KR20120113760A (ko) 2012-10-15
AU2010336533A1 (en) 2012-07-12
WO2011079142A3 (en) 2011-11-24
WO2011079142A2 (en) 2011-06-30
NZ600800A (en) 2014-10-31
US8871933B2 (en) 2014-10-28
EP2515904A4 (en) 2013-07-03
CA2785503A1 (en) 2011-06-30
RU2012131344A (ru) 2014-01-27
CN102834097B (zh) 2015-06-17
US20160024076A1 (en) 2016-01-28
JP2013515737A (ja) 2013-05-09
AU2015243015A1 (en) 2015-11-05
ZA201204759B (en) 2014-03-26
US20110160242A1 (en) 2011-06-30
TW201141865A (en) 2011-12-01
US20140031551A1 (en) 2014-01-30
TWI557125B (zh) 2016-11-11
CO6561823A2 (es) 2012-11-15
MY169232A (en) 2019-03-19
TW201542546A (zh) 2015-11-16
CN102834097A (zh) 2012-12-19
PH12014500310A1 (en) 2015-09-28
HK1215025A1 (zh) 2016-08-12
US8552192B2 (en) 2013-10-08
EP2515904A2 (en) 2012-10-31
AU2010336533B2 (en) 2015-09-10
EP3081567A3 (en) 2016-11-16
SG181927A1 (en) 2012-07-30
US9499540B2 (en) 2016-11-22
MY156701A (en) 2016-03-15
EP3081567A2 (en) 2016-10-19
TW201643163A (zh) 2016-12-16
MX2012007259A (es) 2015-05-15
TWI506026B (zh) 2015-11-01
BR112012015656A2 (pt) 2016-05-10
JP2016041712A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
US9499540B2 (en) Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
TWI615393B (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
AU2025202754A1 (en) Imidazolonylquinoline compounds and therapeutic uses thereof
EP2720546B1 (en) Spiro-cyclic trpv4 antagonists
CN106279147A (zh) 一种吡啶并氮杂环化合物及其制备方法和用途
CN113710668B (zh) 用于ep300或cbp调节及其适应症的缩合吖嗪
KR20190032420A (ko) Fgfr 억제제로서 사용되는 헤테로시클릭 화합물
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof